Diagnostic utility of cytoplasmic 5’-nucleotidase autoantibodies to identify inclusion body myositis patients

Christine Bundell; Rakesh Shakya; Anna Brusch; Andrew McLean Tooke; Peter Hollingsworth; Merrilee Needham

doi:10.1016/j.pathol.2016.12.327

Back

Diagnostic utility of cytoplasmic 5’-nucleotidase autoantibodies to identify inclusion body myositis patients

Journal article

Peer reviewed

Diagnostic utility of cytoplasmic 5’-nucleotidase autoantibodies to identify inclusion body myositis patients

Christine Bundell, Rakesh Shakya, Anna Brusch, Andrew McLean Tooke, Peter Hollingsworth and Merrilee Needham

Pathology, Vol.49(Supplement 1), pp.S112-S113

2017

DOI: https://doi.org/10.1016/j.pathol.2016.12.327

Abstract

Antibodies to the muscle autoantigen cytoplasmic 5’-nucleotidase (C5N) have proved promising as a biomarker for inclusion body myositis (IBM).1 A blood test to support a diagnosis of IBM would potentially reduce the need for muscle biopsy. We have assessed the capacity of this assay to distinguish IBM from other inflammatory myopathies (IM) and other relevant conditions.

Details

Title: Diagnostic utility of cytoplasmic 5’-nucleotidase autoantibodies to identify inclusion body myositis patients
Authors/Creators: Christine Bundell - Pathwest Laboratory Medicine
Rakesh Shakya - Pathwest Laboratory Medicine
Anna Brusch - Sir Charles Gairdner Hospital
Andrew McLean Tooke - Pathwest Laboratory Medicine
Peter Hollingsworth - Pathwest Laboratory Medicine
Merrilee Needham - Fiona Stanley Hospital
Publication Details: Pathology, Vol.49(Supplement 1), pp.S112-S113
Publisher: Elsevier B.V.
Identifiers: 991005623558007891
Murdoch Affiliation: Health Futures Institute; Centre for Molecular Medicine and Innovative Therapeutics
Language: English
Resource Type: Journal article

Metrics

11 Record Views